Stock Research: Glenmark Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Glenmark Pharmaceuticals

NSEI:GLENMARK INE935A01035
61
  • Value
    12
  • Growth
    89
  • Safety
    Safety
    53
  • Combined
    45
  • Sentiment
    80
  • 360° View
    360° View
    61
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. It operates in branded, generics, and OTC segments, focusing on Respiratory, Dermatology, Oncology, diabetes, cardiovascular, and oral contraceptives, with brands like RYALTRIS and SALMEX/ASTHMEX. The company develops products for markets such as India, Russia & CIS, Brazil, Asia, and Africa. In the last fiscal year, the company had a market cap of $7238 million, profits of $1050 million, and revenue of $1559 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 61 (better than 61% compared with alternatives), overall professional sentiment and financial characteristics for the stock Glenmark Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Glenmark Pharmaceuticals. The consolidated Value Rank has an attractive rank of 53, which means that the share price of Glenmark Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 53% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 80. But the company’s financing is risky with a Safety rank of 12. This means 88% of comparable companies have a safer financing structure than Glenmark Pharmaceuticals. ...read more

more
Index
Low Waste
Recycling
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
53 59 71 87
Growth
89 77 23 37
Safety
Safety
12 18 44 29
Sentiment
80 61 32 14
360° View
360° View
61 66 28 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
82 60 31 42
Opinions Change
37 50 38 35
Pro Holdings
n/a 25 21 26
Market Pulse
85 96 73 47
Sentiment
80 61 32 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
53 59 71 87
Growth
89 77 23 37
Safety Safety
12 18 44 29
Combined
45 54 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
62 64 75 89
Price vs. Earnings (P/E)
59 62 84 91
Price vs. Book (P/B)
48 59 81 87
Dividend Yield
29 18 23 40
Value
53 59 71 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
36 67 28 16
Profit Growth
68 98 26 53
Capital Growth
77 3 6 72
Stock Returns
83 95 95 33
Growth
89 77 23 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
27 46 26 18
Refinancing
40 28 76 84
Liquidity
23 14 38 24
Safety Safety
12 18 44 29

Similar Stocks

Discover high‑ranked alternatives to Glenmark Pharmaceuticals and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Dr. Reddy's

BSE:500124
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.